EU and US could reach trade deal this weekend - Reuters
Investing.com -- DexCom saw its stock rise over 5% premarket Monday following the announcement of preliminary, unaudited results for the fourth quarter of 2024 and an optimistic outlook for 2025.
The company said it expects total revenue of at least $1.113 billion for the fourth quarter, marking an 8% increase compared to the same period in 2023.
U.S. revenue is projected to reach approximately $803 million, a 4% increase, while international revenue is expected to hit $310 million, a robust 17% growth over the previous year.
For the full fiscal year 2024, Dexcom’s preliminary revenue is approximately $4.032 billion, reflecting an 11% year-over-year growth.
The company noted that its fourth-quarter gross margin was impacted by a non-cash charge related to inventory damage in transit and certain production issues that affected yield.
“Dexcom made key strategic investments in 2024 that steadily progressed throughout the year, leaving us well positioned to capitalize on our growth opportunity ahead,” said Dexcom’s CEO, Kevin Sayer.
He also said the company plans to build on these investments in 2025.
DXCM anticipates a 14% increase in total revenue for 2025, coming in at $4.60 billion.
The growth is expected to be driven by increased adoption of continuous glucose monitoring (CGM) systems, further international expansion, and the rollout of Dexcom’s Stelo platform.
Additionally, Dexcom (NASDAQ:DXCM) estimates its 2025 Non-GAAP Gross Profit Margin to be between 64% and 65% and its Non-GAAP Operating Margin around 21%.